Alice Bexon

911 total citations
46 papers, 620 citations indexed

About

Alice Bexon is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alice Bexon has authored 46 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 17 papers in Genetics and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alice Bexon's work include Virus-based gene therapy research (9 papers), Estrogen and related hormone effects (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Alice Bexon is often cited by papers focused on Virus-based gene therapy research (9 papers), Estrogen and related hormone effects (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Alice Bexon collaborates with scholars based in United States, United Kingdom and France. Alice Bexon's co-authors include Guadalupe García–Tsao, Arun J. Sanyal, Thomas Boyer, Daniel Carl, Andrés T. Blei, M. Mahjoubi, Jean‐Pierre Armand, D. Méry-Mignard, M. Bonnay and Philippe Rougier and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alice Bexon

43 papers receiving 609 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alice Bexon United States	10	291	200	200	200	118	46	620
Alexander I. Aspinall Canada	10	396 1.4×	173 0.9×	55 0.3×	287 1.4×	164 1.4×	16	632
Aki Kaimori Japan	6	244 0.8×	77 0.4×	109 0.5×	131 0.7×	88 0.7×	6	476
Johan J. van der Reijden Netherlands	10	69 0.2×	54 0.3×	66 0.3×	84 0.4×	91 0.8×	13	368
Shuichi Terasaki Japan	11	316 1.1×	142 0.7×	77 0.4×	253 1.3×	53 0.4×	23	459
Tetsu Oura United States	14	144 0.5×	388 1.9×	91 0.5×	81 0.4×	332 2.8×	26	807
Varnavas Constantinou Greece	12	101 0.3×	88 0.4×	67 0.3×	67 0.3×	101 0.9×	18	485
Yukio KUSUMOTO Japan	12	234 0.8×	68 0.3×	50 0.3×	226 1.1×	31 0.3×	36	508
Chiara Quarneti Italy	13	582 2.0×	207 1.0×	86 0.4×	500 2.5×	85 0.7×	22	782
Antal Csepregi Germany	13	200 0.7×	127 0.6×	88 0.4×	176 0.9×	22 0.2×	27	506
Muhammed Yüksel United Kingdom	11	286 1.0×	185 0.9×	51 0.3×	205 1.0×	166 1.4×	20	539

Countries citing papers authored by Alice Bexon

Since Specialization

Citations

This map shows the geographic impact of Alice Bexon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice Bexon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice Bexon more than expected).

Fields of papers citing papers by Alice Bexon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice Bexon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice Bexon. The network helps show where Alice Bexon may publish in the future.

Co-authorship network of co-authors of Alice Bexon

This figure shows the co-authorship network connecting the top 25 collaborators of Alice Bexon. A scholar is included among the top collaborators of Alice Bexon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice Bexon. Alice Bexon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dulloo, Sean, Simon Lord, Dean A. Fennell, et al.. (2024). Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.. Journal of Clinical Oncology. 42(16_suppl). TPS8124–TPS8124. 2 indexed citations

Iyer, Swaminathan P., Steven M. Horwitz, Salvia Jain, et al.. (2024). Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL). Blood. 144(Supplement 1). 7223–7223.

Fennell, Dean A., Sean Dulloo, Simon Lord, et al.. (2024). First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).. Journal of Clinical Oncology. 42(16_suppl). 3019–3019. 5 indexed citations

Dulloo, Sean, Dean A. Fennell, Fiona Thistlethwaite, et al.. (2022). 1643TiP First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors. Annals of Oncology. 33. S1292–S1293. 2 indexed citations

Daniel, Weston L., et al.. (2022). A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. Frontiers in Immunology. 13. 1073777–1073777. 20 indexed citations

Iwamoto, Fábio M., Vinai Gondi, Nicholas Butowski, et al.. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 24(Supplement_7). vii83–vii83. 2 indexed citations

Naik, Shruthi, Bradley C. Leibovich, Tanner Miest, et al.. (2022). Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.. Journal of Clinical Oncology. 40(6_suppl). 509–509. 7 indexed citations

Milhem, Mohammed, Cesar A. Perez, Glenn J. Hanna, et al.. (2020). AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology. 38(15_suppl). TPS3164–TPS3164. 5 indexed citations

Merchan, Jaime R., Manish R. Patel, Steven Powell, et al.. (2018). Tracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy. Annals of Oncology. 29. viii479–viii480. 1 indexed citations

10.

Powell, Steven, Manish R. Patel, Jaime R. Merchan, et al.. (2018). VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors. Annals of Oncology. 29. viii439–viii439. 2 indexed citations

11.

Jayaram, Anuradha, Karolina Nowakowska, Joaquı́n Mateo, et al.. (2017). Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status. Annals of Oncology. 28. vii30–vii30. 3 indexed citations

12.

Cottu, Paul, Antoîne Italiano, Andréa Varga, et al.. (2015). Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study.. Journal of Clinical Oncology. 33(15_suppl). 5593–5593. 2 indexed citations

13.

Jayaram, Anuradha, Karolina Nowakowska, Joaquı́n Mateo, et al.. (2015). Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.. Journal of Clinical Oncology. 33(15_suppl). 5051–5051. 1 indexed citations

14.

Ruzsa, Ágnes, Mehmet Şen, Mark D. Evans, et al.. (2014). Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Investigational New Drugs. 32(6). 1278–1284. 46 indexed citations

15.

Smith, David A., Paul Conkling, Donald Richards, et al.. (2014). Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunology Immunotherapy. 63(8). 787–796. 58 indexed citations

16.

Siegel, David S., Andrew McDonald, Nicolás Novitzky, et al.. (2014). Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies. Blood. 124(21). 4464–4464. 1 indexed citations

17.

Boyer, Thomas, Arun J. Sanyal, Guadalupe García–Tsao, et al.. (2011). Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transplantation. 17(11). 1328–1332. 84 indexed citations

18.

Ghalib, R., et al.. (2010). 32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS. Journal of Hepatology. 52. S14–S14. 6 indexed citations

19.

Boyer, Thomas, Arun J. Sanyal, Guadalupe García–Tsao, et al.. (2010). Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. Journal of Hepatology. 55(2). 315–321. 166 indexed citations

20.

Patt, Yehuda Z., James E. Liebmann, Sabine Eckhardt, et al.. (2007). Capecitabine Plus 3-Weekly Irinotecan (XELIRI Regimen) as First-Line Chemotherapy for Metastatic Colorectal Cancer. American Journal of Clinical Oncology. 30(4). 350–357. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact